Moderna Inc (NASDAQ:MRNA, ETR:0QF) has dosed the first patient in a clinical trial of its experimental mRNA-2808 therapy for relapsed or refractory multiple myeloma — a milestone that marks the company’s first true step into cancer immunotherapy using its messenger-RNA technology.
For a business still best known for its COVID-19 vaccine, the move underscores Moderna’s ongoing effort to redefine itself beyond the pandemic era and prove that its mRNA platform can power a broader class of medicines.
The Phase 1/2 study will evaluate safety, tolerability and preliminary anti-tumour activity in adults whose disease has returned or failed to respond to existing treatments. The first dose was administered at SCRI Oncology Partners in Nashville, in collaboration with the Sarah Cannon Research Institute network in the United States.
“This is an important milestone as it is Moderna’s first T-cell engager therapy to be dosed in a patient,” said Dr Kyle Holen, Moderna’s head of oncology development.
“Given the vast unmet needs in multiple myeloma, I believe we can help improve the lives of these patients with innovative therapies,” he added. “Our mRNA platform uniquely allows for the multiplexing of several T-cell engager targets, designed to attack the disease from multiple angles to overcome, reduce and prevent escape mechanisms.”
How it works
Unlike the company’s well-known vaccine candidates, mRNA-2808 is not designed to trigger an immune response against a virus. Instead, it delivers a single strand of genetic code that instructs the body’s own cells to produce three distinct T-cell engager (TCE) proteins, each targeting a separate antigen commonly expressed on myeloma cells.
T-cell engagers are engineered molecules that bind to both a cancer cell and a T-cell, bringing them into close proximity so the immune system can attack the tumour. Moderna’s “multiplexed” approach aims to broaden tumour recognition and potentially limit resistance — a key challenge in multiple myeloma, where the cancer often evolves to escape single-target therapies.
If successful, mRNA-2808 could represent a new generation of on-demand biologics: rather than manufacturing complex protein therapies in a bioreactor, the patient’s own body becomes the factory, guided by messenger RNA.
Why this matters
Multiple myeloma remains an incurable blood cancer despite major advances from CAR-T and antibody-based therapies. Approved T-cell engagers from Johnson & Johnson and Pfizer have shown strong responses, but they’re difficult to manufacture and can trigger severe immune-related side effects.
mRNA delivery could simplify production, allow rapid redesign if resistance develops, and potentially reduce costs — all attractive qualities in a market projected to exceed US$30 billion this decade. Moderna hopes its platform’s flexibility will give it an edge as combination and personalised immunotherapies gain ground.
The trial will begin with a dose-escalation phase before expanding into larger patient cohorts. Early safety and biomarker data are expected to guide next steps, though efficacy results are likely some distance away.
Expanding the oncology pipeline
mRNA-2808 is one of several oncology candidates in Moderna’s pipeline, which also includes Intismeran autogene (formerly mRNA-4157), a personalised cancer vaccine in collaboration with Merck & Co., and mRNA-2752, a cytokine-based immune stimulator for solid tumours.
Together, these programs show how Moderna is repositioning its platform beyond infectious diseases and towards therapeutic areas where immune modulation is key. The company has highlighted oncology as a central pillar of its long-term growth strategy, alongside respiratory and rare-disease applications.
Market context
Shares in Moderna closed Monday at US $24.91, down 8.3% on the session and roughly 40% lower year-to-date, reflecting broader investor caution across the biotech sector and ongoing pressure on COVID-vaccine revenues. Analysts noted that while early oncology studies won’t affect near-term earnings, successful proof-of-concept data could materially expand the company’s long-term addressable market.
For now, markets appear content to wait for evidence — but scientifically, the trial marks an inflection point. Moderna’s ability to translate its mRNA expertise from infectious-disease prevention to cancer treatment will be closely watched across the industry.
What’s next
The first-in-human results for mRNA-2808 will provide a glimpse into whether multiplexed T-cell engagement via mRNA can safely and effectively target complex cancers. If it works, the concept could extend well beyond multiple myeloma to solid tumours and other haematological malignancies.
For a company still defined by its pandemic success, Moderna’s oncology venture is a reminder that the story of mRNA medicine may only just be entering its next phase.